Royalty Pharma plc announced on February 12, 2025, an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab. This investigational drug candidate is in Phase 3 development for both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).
Under the terms of the transaction, Royalty Pharma will provide up to $250 million over six quarters, including an upfront payment of $50 million, to support the development of litifilimab. In exchange, Royalty Pharma will receive regulatory milestones and mid-single-digit royalties on annual worldwide sales.
Litifilimab has demonstrated proof-of-concept in SLE and CLE, with Phase 3 results expected between 2026 and 2027. SLE affects over 3 million patients worldwide, and litifilimab has the potential to be a first-in-disease medicine for CLE, addressing a high unmet medical need and expanding Royalty Pharma's development-stage portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.